نتائج البحث - "Barry R, Davies"

1

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

المصدر: Communications Biology
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)

مصطلحات موضوعية: Male, 0301 basic medicine, Drug, Dendrimers, QH301-705.5, media_common.quotation_subject, bcl-X Protein, Medicine (miscellaneous), Drug development, Antineoplastic Agents, Mice, SCID, Pharmacology, Conjugated system, Article, General Biochemistry, Genetics and Molecular Biology, Mice, 03 medical and health sciences, Targeted therapies, Dogs, 0302 clinical medicine, Therapeutic index, Neoplasms, Dendrimer, Tumor Cells, Cultured, Animals, Humans, Medicine, Biology (General), Rats, Wistar, media_common, Haematological cancer, business.industry, Xenograft Model Antitumor Assays, Rats, Mice, Inbred C57BL, Therapeutic Index, 030104 developmental biology, Proto-Oncogene Proteins c-bcl-2, Tolerability, 030220 oncology & carcinogenesis, Drug delivery, Female, General Agricultural and Biological Sciences, business, Conjugate

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f928851dba9fe7a39b683d8c12e8a5dTest
https://doi.org/10.1038/s42003-020-01631-8Test

2

A pharmacokinetic-pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055

المؤلفون: James W.T. Yates, Karen Woods, Robert W. Wilkinson, Sarah V. Holt, Kirsty Payne, Barry R. Davies, Armelle Logie, Sylvie Guichard

المصدر: British Journal of Pharmacology. 174:2652-2661

مصطلحات موضوعية: 0301 basic medicine, Pharmacology, business.industry, In vitro, 03 medical and health sciences, Route of administration, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, MTOR Kinase Inhibitor AZD8055, chemistry, Pharmacokinetics, In vivo, 030220 oncology & carcinogenesis, Pharmacodynamics, Medicine, Growth inhibition, business, PI3K/AKT/mTOR pathway

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c7c579c415311078d93d157fb8710067Test
https://doi.org/10.1111/bph.13886Test

3

Abstract 56: AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-xL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumor models

المؤلفون: Barry R. Davies, Guangnong Sunny Zhang, Areya Tabatabai, Giulia Fabbri, Francis D. Gibbons, Justin Cidado, Marianne Ashford, Lorraine Graham, Shenghua Wen, Srividya B. Balachander

المصدر: Cancer Research. 80:56-56

مصطلحات موضوعية: Cancer Research, Venetoclax, medicine.drug_class, Cell growth, Cancer, Pharmacology, medicine.disease, Chemotherapy regimen, Tyrosine-kinase inhibitor, chemistry.chemical_compound, Oncology, chemistry, Apoptosis, medicine, IC50, Etoposide, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::de4d5bcc8843a168ac32eeab151dc44bTest
https://doi.org/10.1158/1538-7445.am2020-56Test

4

Abstract 1718: Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index

المؤلفون: Eric Gangl, Francis D. Gibbons, William McCoull, Martin Wild, Lorraine Graham, Hill Kathryn Jane, Brian Kelly, Srividya B. Balachander, David J. Owen, Sean Redmond, Marianne Ashford, Barry R. Davies, Alexander R. Harmer, Shenghua Wen, Iain Grant, Sonya Gales

المصدر: Cancer Research. 80:1718-1718

مصطلحات موضوعية: Cancer Research, Therapeutic index, Oncology, Tolerability, Chemistry, In vivo, Dendrimer, Pharmacology, Nanocarriers, Linker, Controlled release, Conjugate

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8cc5b5a8344d601e4a673da8cfe48853Test
https://doi.org/10.1158/1538-7445.am2020-1718Test

5

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

المؤلفون: Stephen Green, Sylvie Guichard, Robert McEwen, Barry R. Davies, Urszula M. Polanska, Zoe Howard, Teresa Klinowska, Celina M. D'Cruz, Michael Grondine, Christine M. Chresta, Teeru Bihani, Graham Bigley, James W.T. Yates, Kurt Gordon Pike, Jon Curwen, Sabina Cosulich, Oona Delpuech, Martin Pass

المصدر: Molecular Cancer Therapeutics. 14:2508-2518

مصطلحات موضوعية: Cancer Research, Morpholines, Immunoblotting, Breast Neoplasms, Mechanistic Target of Rapamycin Complex 2, Mice, SCID, mTORC1, Mechanistic Target of Rapamycin Complex 1, Biology, Pharmacology, mTORC2, Drug Administration Schedule, Mice, Inbred NOD, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, medicine, Animals, Humans, Fulvestrant, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, Cell Proliferation, Mice, Knockout, Serine/threonine-specific protein kinase, Estradiol, Cell growth, TOR Serine-Threonine Kinases, Xenograft Model Antitumor Assays, Tumor Burden, HEK293 Cells, Pyrimidines, Receptors, Estrogen, Oncology, Multiprotein Complexes, Benzamides, MCF-7 Cells, Hormonal therapy, Female, Signal Transduction, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689b8ba235f8b435652d9591e5d9196fTest
https://doi.org/10.1158/1535-7163.mct-15-0365Test

6

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

المؤلفون: Phillippa Dudley, Neil H. James, Claire Crafter, John Vincent, Barry R. Davies, Teresa Klinowska, Eric Tang

المصدر: International Journal of Oncology

مصطلحات موضوعية: MAPK/ERK pathway, Cancer Research, Receptor, ErbB-2, feedback, Breast Neoplasms, Pharmacology, Biology, Receptor tyrosine kinase, combination therapy, Mice, Trastuzumab, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, medicine, PI3K/AKT/mTOR, Animals, Humans, Pyrroles, HER2-amplified breast cancer, skin and connective tissue diseases, Protein kinase B, PI3K/AKT/mTOR pathway, Cell Proliferation, Cell growth, Gene Amplification, Cancer, Drug Synergism, Articles, medicine.disease, Xenograft Model Antitumor Assays, AZD5363, Pyrimidines, Oncology, Drug Resistance, Neoplasm, MCF-7 Cells, Quinazolines, biology.protein, Phosphorylation, Female, Proto-Oncogene Proteins c-akt, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16a0e9136df3078b9af2fd2524426a6Test
https://doi.org/10.3892/ijo.2015.3062Test

7

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

المصدر: Molecular Cancer Therapeutics. 14:48-58

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0de79ea05648a8f13f0ac9f05b31f90Test
https://doi.org/10.1158/1535-7163.mct-14-0406Test

8

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL

المصدر: Blood. 130(3)

مصطلحات موضوعية: 0301 basic medicine, Apoptosis, Pharmacology, Biochemistry, Tyrosine-kinase inhibitor, chemistry.chemical_compound, Mice, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, Piperidines, hemic and lymphatic diseases, Agammaglobulinaemia Tyrosine Kinase, Phosphoinositide-3 Kinase Inhibitors, Oxadiazoles, biology, NF-kappa B, Drug Synergism, Hematology, Protein-Tyrosine Kinases, Gene Expression Regulation, Neoplastic, Drug Combinations, Organ Specificity, 030220 oncology & carcinogenesis, Ibrutinib, Lymphoma, Large B-Cell, Diffuse, Signal transduction, Signal Transduction, medicine.drug_class, Immunology, Antineoplastic Agents, Proto-Oncogene Proteins c-myc, 03 medical and health sciences, medicine, Animals, Humans, Pyrroles, Protein kinase B, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, Phosphoinositide 3-kinase, Akt inhibitor AZD5363, Adenine, PTEN Phosphohydrolase, Germinal center, Cell Biology, Xenograft Model Antitumor Assays, 030104 developmental biology, Pyrimidines, chemistry, biology.protein, Cancer research, Pyrazoles, Drug Screening Assays, Antitumor, Proto-Oncogene Proteins c-akt

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b7729777f360eff7908ecbecbfbd4dTest
https://pubmed.ncbi.nlm.nih.gov/28729335Test

9

Abstract P3-05-04: AKT antagonist AZD5363 targets estrogen receptor (ER) function in endocrine resistant breast cancer (BC) and synergises with fulvestrant in vivo

المؤلفون: Stephanie K. Guest, Lesley-Ann Martin, Sunil Pancholi, Barry R. Davies, Nikiana Simigdala, Ricardo Ribas, Qiong Gao, Stephen R. D. Johnston, Aradhana Rani, Mitch Dowsett

المصدر: Cancer Research. 75:P3-05

مصطلحات موضوعية: Cancer Research, Fulvestrant, biology, business.industry, Estrogen receptor, Cancer, Pharmacology, medicine.disease, Receptor tyrosine kinase, Oncology, medicine, biology.protein, Endocrine system, business, Protein kinase B, Tamoxifen, PI3K/AKT/mTOR pathway, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::7ac4ec31d93e53105d05abfdecf2002dTest
https://doi.org/10.1158/1538-7445.sabcs14-p3-05-04Test

10

Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases

المصدر: Journal of Medicinal Chemistry. 56:2059-2073

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e89f0e75ec3075ae6b777ac8b9c2c94Test
https://doi.org/10.1021/jm301762vTest

تنقيح النتائج